Business
SFX-01 data published in peer reviewed journal
SFX-01 data published in peer reviewed journal.
About this update from Theracryf Plc
[{"type":"text","content":"\n \nRNS Number : 8089R Evgen Pharma PLC 05 March 2019 \n\n \n\n\n\n\nFor immediate release\n\n\n5 March 2019\n\n\n\n\n \n \n \n \n \nEvgen Pharma plc\n(\"Evgen Pharma\" or \"the Company\")\n \nSFX-01 data published in Peer Reviewed Journal\nEvgen's SFX-01 reduces residual disability in a model of relapsing-remitting multiple sclerosis\nEvgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce the publication in a peer-reviewed scientific journal showing that its lead product, SFX-01, reduced residual disability in a model of relapsing-remitting multiple sclerosis (\"MS\").\nThe paper, \"SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis\", has been published in the journal Multiple Sclerosis and Related Disorders and describes the work undertaken by researchers to test the efficacy of SFX-01 in murine relapsing experimental autoimmune encephalomyelitis, a model of MS. The data demonstrated that SFX-01 reduced residual disability both prophylactically and after disease induction. Most of this effect was mediated by a decrease in maximum severity of relapses and improved recovery during follow-up. Histological examination of the spinal cord was consistent with the clinical findings, with improvement in demyelination and the number of apoptotic cells, but not inflammatory cell infiltration.\nThe publication follows Evgen's presentation of its preclinical study data of SFX-01 in various models of the relapsing remitting form of multiple sclerosis at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) .\nThe paper can be viewed at: https://www.msard-journal.com/article/S2211-0348(19)30104-X/fulltext (Ian Galea et al; SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis, Multiple Sclerosis and Related Disorders, 2019).\nSteve Franklin, CEO of Evgen Pharma, commented:\n\"The leading product in MS treatment generates revenues of several billion dollars per annum despite an adverse side effect profile. There is an attractive opportunity for oral disease-modifying agents with comparable or better efficacy and an improved side-effect profile.\"\nIan Galea, Associate Professor in Experimental N...